OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS | Market Closed - Börse Stuttgart 02:14:42 2024-06-28 EDT | ||
| 0.16 EUR | +33.33% |
|
| Current month | +6.67% | ||
| 1 month | -38.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.16 | +33.33% |
| 24-06-27 | 0.12 | -7.69% |
| 24-06-26 | 0.13 | -18.75% |
| 24-06-25 | 0.16 | 0.00% |
| 24-06-24 | 0.16 | -5.88% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:14 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX38AG |
| ISIN | DE000LX38AG1 |
| Date issued | 2024-05-27 |
| Strike | 0.7532 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.55 € |
|---|---|
| Lowest since issue | 0.12 € |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2023, the group has a portfolio of a product in phase II-B clinical development (Varoglutamstat; PQ912).
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.85
EUR
Average target price
41.57
EUR
Spread / Average Target
+2,146.85%
- Stock Market
- Certificates
- Certificat
